Benitec Biopharma Inc
BNTC11.605USD
+0.645+5.89%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
296.46MCap. mercado
PérdidaP/E TTM
Más Datos de Benitec Biopharma Inc Compañía
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Información de la empresa
Símbolo de cotizaciónBNTC
Nombre de la empresaBenitec Biopharma Inc
Fecha de salida a bolsaJul 11, 2012
Director ejecutivoDr. Jerel A. Banks, M.D., Ph.D.
Número de empleados16
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 11
Dirección3940 Trust Way
CiudadHAYWARD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94545
Teléfono15107800819
Sitio Webhttps://benitec.com/
Símbolo de cotizaciónBNTC
Fecha de salida a bolsaJul 11, 2012
Director ejecutivoDr. Jerel A. Banks, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward F. Smith
Mr. Edward F. Smith
Independent Director
Independent Director
--
--
Mr. J. Kevin Buchi, CPA
Mr. J. Kevin Buchi, CPA
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Megan Joan Boston
Ms. Megan Joan Boston
Chief Financial Officer, Executive Director, Secretary
Chief Financial Officer, Executive Director, Secretary
25.93K
--
Mr. Peter Damian Francis
Mr. Peter Damian Francis
Independent Director
Independent Director
297.00
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Managing Director
Managing Director
--
--
Dr. Jerel A. Banks, M.D., Ph.D.
Dr. Jerel A. Banks, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Sophie Mukadam
Ms. Sophie Mukadam
Chief Operating Officer
Chief Operating Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2023
FY2022
FY2021
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Licensing revenue
75.00K
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Licensing revenue
75.00K
0.00%
Estadísticas de accionistas
Actualizado: vie., 23 de may
Actualizado: vie., 23 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
37.62%
Janus Henderson Investors
11.12%
Franklin Advisers, Inc.
10.90%
Adage Capital Management, L.P.
7.51%
HBM Partners AG
3.97%
Other
28.88%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
51.24%
Investment Advisor/Hedge Fund
24.03%
Investment Advisor
9.80%
Corporation
2.84%
Research Firm
0.33%
Individual Investor
0.27%
Other
11.48%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
68
23.23M
88.49%
+3.01M
2025Q1
66
23.17M
88.28%
+2.93M
2024Q4
60
20.95M
89.36%
+4.31M
2024Q3
56
15.45M
85.62%
+7.92M
2024Q2
55
8.11M
85.06%
+2.49M
2024Q1
53
1.49M
56.66%
-268.80K
2023Q4
54
1.42M
56.57%
-342.85K
2023Q3
57
1.50M
61.34%
-154.56K
2023Q2
56
827.91K
52.26%
-194.13K
2023Q1
56
861.88K
54.33%
-200.92K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
9.88M
37.62%
+916.50K
+10.23%
Mar 31, 2025
Janus Henderson Investors
2.92M
11.12%
+302.52K
+11.56%
Mar 31, 2025
Franklin Advisers, Inc.
2.86M
10.9%
-78.56K
-2.67%
Mar 31, 2025
Adage Capital Management, L.P.
1.97M
7.51%
--
--
Mar 31, 2025
HBM Partners AG
1.04M
3.97%
+200.27K
+23.80%
Dec 31, 2024
Nantahala Capital Management, LLC
838.10K
3.19%
--
--
Mar 31, 2025
Nemean Asset Management, LLC
746.32K
2.84%
+648.12K
+659.98%
Apr 22, 2024
INFINITUM ASSET MANAGEMENT, LLC
475.00K
1.81%
+265.00K
+126.19%
Mar 31, 2025
The Vanguard Group, Inc.
327.03K
1.25%
+27.01K
+9.00%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
261.76K
1%
+1.35K
+0.52%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Health Care ETF
0.62%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 ETF
0%
Simplify Health Care ETF
Proporción0.62%
iShares Micro-Cap ETF
Proporción0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Fecha
Tipo
Relación
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
Jul 25, 2023
Merger
17<1
